Why did HCA raise its 2025 guidance?

Management raised 2025 ranges for revenue, Adjusted EBITDA, net income, and EPS following a strong third quarter. Adjusted EBITDA guidance moved up by $550 million at both the low and high ends, and EPS guidance rose by $1.50 at the low end and $1.00 at the high end. The release attributes results to volume growth, disciplined execution, and an expected mostly stable operating environment.

How much of the EPS growth came from operations versus share buybacks?

Net income attributable to HCA grew 29.4%, while diluted EPS grew 42.6%. The gap reflects a 9.2% reduction in weighted diluted shares (236.2 million vs. 259.9 million) after repurchases of $7.509 billion over the first nine months. Buybacks therefore contributed a meaningful part of per-share growth, though operating income and EBITDA growth were also strong.

Are there any one-time items that flatter the year-over-year comparison?

Partly. Q3 2024 included about $50 million (about $0.15 per diluted share) of revenue loss and extra expense from Hurricane Helene, which makes the prior-year base easier to beat. Also, the nine-month 2024 figures included a $209 million gain on facility sales, while 2025 showed only a $4 million loss, which affects GAAP comparisons. Adjusted metrics exclude these facility gains and losses.

What are the main risks to HCA's outlook?

The filing highlights the scheduled expiration of enhanced ACA premium tax credits after December 31, 2025, which could reduce insured volumes and increase uninsured or underinsured patients. It also cites Medicaid and state directed payment changes under the One Big Beautiful Bill Act, sequestration cuts to Medicare, tariff and supply cost pressures, labor costs, and the lingering impact of the 2024 hurricanes. Guidance excludes future approvals of state Medicaid directed and supplemental payments, so those represent potential upside that is not yet modeled.

How leveraged is HCA, and can it sustain shareholder returns?

Total debt was $44.511 billion at September 30, 2025, against $997 million of cash, and the company has $6.076 billion of credit facility availability. Operating cash flow of $4.416 billion in the quarter and $10.277 billion year to date covered capital expenditures of about $3.5 billion year to date and funded buybacks and dividends. However, the stockholders' deficit widened to $(5.335) billion, and debt has increased from year-end 2024, so continued buybacks depend on sustained cash generation and the ability to refinance maturities on acceptable terms.

HCA 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed October 24, 2025. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported third-quarter 2025 results that beat its own prior trajectory and raised full-year 2025 guidance.

Revenue rose 9.6% year over year to $19.161 billion^a, and net income attributable to HCA grew 29.4% to $1.643 billion, or $6.96 per diluted share (up 42.6%). Adjusted EBITDA increased 18.5% to $3.870 billion, with the margin expanding to 20.2% from 18.7%. Operating volume was steady-to-better: same facility admissions rose 2.1%, same facility equivalent admissions rose 2.4%, and same facility revenue per equivalent admission increased 6.6%.

Part of the year-over-year comparison benefits from Q3 2024 being depressed by roughly $50 million^b (about $0.15 per share) of Hurricane Helene impacts. Management raised 2025 guidance across the board. Revenue is now expected at $75.0 to $76.5 billion (previously $74.0 to $76.0 billion), Adjusted EBITDA at $15.25 to $15.65 billion (previously $14.7 to $15.3 billion), and diluted EPS at $27.00 to $28.00 (previously $25.50 to $27.00).

Capital expenditures are estimated at about $5.0 billion^c. Cash generation was strong, with operating cash flow of $4.416 billion in the quarter. HCA also repurchased 6.514 million shares for $2.498 billion and retains $3.256 billion under its authorization, while the board declared a $0.72 quarterly dividend payable December 29, 2025.

The balance sheet carries meaningful leverage: total debt of $44.511 billion^d against cash of $997 million, and stockholders' deficit attributable to HCA widened to $(5.335) billion. Investors should weigh the strong earnings and buyback-driven per-share growth against this leverage and ongoing policy risks, including the scheduled expiration of enhanced ACA premium tax credits after December 31, 2025, Medicaid funding changes under the One Big Beautiful Bill Act, and sequestration.

02—Key points

Key Highlights

Q3 2025 revenue grew 9.6% to $19.161 billion; Adjusted EBITDA rose 18.5% to $3.870 billion, with margin expanding to 20.2% from 18.7%.
Diluted EPS increased 42.6% to $6.96, helped by a 9.2% reduction in diluted share count (236.2 million vs. 259.9 million) from aggressive buybacks.
Full-year 2025 guidance raised: Adjusted EBITDA to $15.25–$15.65 billion (from $14.7–$15.3 billion) and diluted EPS to $27.00–$28.00 (from $25.50–$27.00).
Same facility admissions +2.1%, equivalent admissions +2.4%, and same facility revenue per equivalent admission +6.6%, indicating both volume and pricing/mix gains.
Q3 operating cash flow was $4.416 billion vs. $3.515 billion a year earlier; the company repurchased $2.498 billion of stock in the quarter with $3.256 billion left on its authorization.
Leverage remains high: total debt of $44.511 billion, cash of $997 million, and a stockholders' deficit attributable to HCA of $(5.335) billion.
Quarterly dividend of $0.72 per share declared, payable December 29, 2025 to holders of record on December 15, 2025.

03—Questions

Frequently Asked Questions

Why did HCA raise its 2025 guidance?
Management raised 2025 ranges for revenue, Adjusted EBITDA, net income, and EPS following a strong third quarter. Adjusted EBITDA guidance moved up by $550 million at both the low and high ends, and EPS guidance rose by $1.50 at the low end and $1.00 at the high end. The release attributes results to volume growth, disciplined execution, and an expected mostly stable operating environment.
How much of the EPS growth came from operations versus share buybacks?
Net income attributable to HCA grew 29.4%, while diluted EPS grew 42.6%. The gap reflects a 9.2% reduction in weighted diluted shares (236.2 million vs. 259.9 million) after repurchases of $7.509 billion over the first nine months. Buybacks therefore contributed a meaningful part of per-share growth, though operating income and EBITDA growth were also strong.
Are there any one-time items that flatter the year-over-year comparison?
Partly. Q3 2024 included about $50 million (about $0.15 per diluted share) of revenue loss and extra expense from Hurricane Helene, which makes the prior-year base easier to beat. Also, the nine-month 2024 figures included a $209 million gain on facility sales, while 2025 showed only a $4 million loss, which affects GAAP comparisons. Adjusted metrics exclude these facility gains and losses.
What are the main risks to HCA's outlook?
The filing highlights the scheduled expiration of enhanced ACA premium tax credits after December 31, 2025, which could reduce insured volumes and increase uninsured or underinsured patients. It also cites Medicaid and state directed payment changes under the One Big Beautiful Bill Act, sequestration cuts to Medicare, tariff and supply cost pressures, labor costs, and the lingering impact of the 2024 hurricanes. Guidance excludes future approvals of state Medicaid directed and supplemental payments, so those represent potential upside that is not yet modeled.
How leveraged is HCA, and can it sustain shareholder returns?
Total debt was $44.511 billion at September 30, 2025, against $997 million of cash, and the company has $6.076 billion of credit facility availability. Operating cash flow of $4.416 billion in the quarter and $10.277 billion year to date covered capital expenditures of about $3.5 billion year to date and funded buybacks and dividends. However, the stockholders' deficit widened to $(5.335) billion, and debt has increased from year-end 2024, so continued buybacks depend on sustained cash generation and the ability to refinance maturities on acceptable terms.

04—Continue

← View all 8-K filings